Clinical Effect of Infrared Liver Disease Treatment Device and Tenofovir Alafenamide Fumarate in the Treatment of Chronic Hepatitis B

HE Xiongzhi

doi:10.14033/j.cnki.cfmr.2025.06.011

Abstract：Objective:To explore the clinical efficacy of infrared liver disease treatment device and tenofovir alafenamide fumarate(TAF)in the treatment of chronic hepatitis B(CHB).Method:A total of 98 CHB patients admitted to the Affiliated Hospital of Putian University from May 2021 to July 2023 were selected as the study objects and divided into study group(n=49)and control group(n=49)by random number table method.The control group was given TAF treatment,and the study group was given infrared liver disease therapy combined with TAF treatment.The clinical efficacy,viral negative conversion rate,liver function and inflammatory factors of the two groups were compared.Result:After treatment,the total effective rate of the study group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the negative conversion rates of hepatitis B virus deoxyribonucleic acid(HBV-DNA)and hepatitis Be antigen(HBeAg)in the study group were higher than those in the control group,and the difference was statistically significant(P<0.05).After 3 months of treatment,the levels of alanine aminotransferase(ALT),aspartate transaminase(AST)and total bilirubin(TBIL)in two groups were decreased,and the study group was lower than the control group,the difference was statistically significant(P<0.05).After 3 months of treatment,the levels of tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)in two groups decreased,and the study group was lower than the control group,and the difference was statistically significant(P<0.05).Conclusion:Infrared liver therapy instrument combined with TAF for the treatment of CHB can improve clinical efficacy,promote the negative transformation of virology indicators,improve liver function,and alleviate inflammation in the body.